London's Royal Free hospital is among several in the world that are working on the futuristic idea of growing custom-made organs in the lab Few have received the lab-made organs so far - including ears and windpipes - but researchers hope they will soon transplant more They hope to transplant world's first nose made partly from stem cells

By Associated Press and Ellie Zolfagharifard

Published: 05:38 EST, 8 April 2014 | Updated: 12:09 EST, 8 April 2014

664 shares

56

View comments

At London's Royal Free hospital, scientists are growing noses, ears and blood vessels in the laboratory in a bold attempt to make body parts using stem cells.

It is among several labs around the world, including in the U.S., that are working on the futuristic idea of growing custom-made organs in the lab.

Only a handful of patients have received the British lab-made organs so far - including tear ducts, blood vessels and windpipes.

But researchers hope they will soon be able to transplant more types of body parts into patients, including what would be the world's first nose made partly from stem cells.

Excerpt from:
British scientists make custom-made body parts using stem cells

A genetic tweak can make light work of some nervous disorders. Using flashes of light to stimulate modified neurons can restore movement to paralysed muscles. A study demonstrating this, carried out in mice, lays the path for using such "optogenetic" approaches to treat nerve disorders ranging from spinal cord injury to epilepsy and motor neuron disease.

Optogenetics has been hailed as one of the most significant recent developments in neuroscience. It involves genetically modifying neurons so they produce a light-sensitive protein, which makes them "fire", sending an electrical signal, when exposed to light.

So far optogenetics has mainly been used to explore how the brain works, but some groups are exploring using it as therapy. One stumbling block has been fears about irreversibly genetically manipulating the brain.

In the latest study, a team led by Linda Greensmith of University College London altered mouse stem cells in the lab before transplanting them into nerves in the leg this means they would be easier to remove if something went wrong.

"It's a very exciting approach that has a lot of potential," says Ziv Williams of Harvard Medical School in Boston.

Greensmith's team inserted an algal gene that codes for a light-responsive protein into mouse embryonic stem cells. They then added signalling molecules to make the stem cells develop into motor neurons, the cells that carry signals to and from the spinal cord to the rest of the body. They implanted these into the sciatic nerve which runs from the spinal cord to the lower limbs of mice whose original nerves had been cut.

After waiting five weeks for the implanted neurons to integrate with the muscle, Greensmith's team anaesthetised the mice, cut open their skin and shone pulses of blue light on the nerve. The leg muscles contracted in response. "We were surprised at how well this worked," says Greensmith.

Most current approaches being investigated to help people who are paralysed involve electrically stimulating their nerves or muscles. But this can be painful because they may still have working pain neurons. Plus, the electricity makes the muscles contract too forcefully, making them tire quickly.

Using the optogenetic approach, however, allows the muscle fibres to be stimulated more gently, because the light level can be increased with each pulse. "It gives a very smooth contraction," says Greensmith.

To make the technique practical for use in people, the researchers are developing a light-emitting diode in the form of a cuff that would go around the nerve, which could be connected to a miniature battery pack under the skin.

View original post here:
Muscle paralysis eased by light-sensitive stem cells

Irvine, CA (PRWEB) April 03, 2014

DrSkinSpa.com is a top-tier skin care web-retail store. It places its primary focus on bringing clinically tested skin care creations that are manufactured using naturally derived ingredients. The company proudly markets an extensive line of natural and effective anti wrinkle cream skin products. Skin care rejuvenators are just one of the many categories of beauty products sold here and DrSkinSpa.com has just added Eminence Bamboo Firming Fluid, 1.2 oz. to its extensive line.

The organic skin care product that is Eminence Bamboo Firming Fluid, 1.2 oz., contains an abundance of plant ingredients, essential oils, and anti-aging Swiss Green Apple Stem Cells. When placed together in this anti aging products, wrinkles and lines are smoothed, hydrated, and the skin is firmed up for a younger appearance.

The key ingredients in Eminence Bamboo Firming Fluid, 1.2 oz. include bamboo, both coconut oil and water, a natural retinol alternative complex with chicory root and tara tree, Swiss Green Apple Stem Cells, and monoi, a fragrant and firming Tahitian oil.

Bamboo has both soluble and insoluble fiber, free-radical fighting antioxidants, proteins, skin-enriching vitamins and minerals to help firm and anti age skin. Coconut oil is included in Eminence Bamboo Firming Fluid, 1.2 oz., for its moisturizing effects, which also help restore skins natural moisture barrier. This oil also works as an antioxidant. The coconut water in this serum balances the skins pH, returning moisture to skin; it also tones the complexion. Coconut water has natural reserves of Vitamin C, electrolytes, calcium, potassium and phosphorous, all plusses for both skin and body.

The Natural Retinol Alternative Complex in Eminence Bamboo Firming Fluid, 1.2 oz., is a combination of chicory root natural sugars (oligosaccharides) and tara tree. The sugars from chicory root firm up loose and sagging skin with immediate activity. It also increases collagen synthesis. Tara tree provides long-lasting moisture.

Dr. Farid Mostamand, owner of DrSkinSpa.com, says, Eminence Bamboo Firming Fluid, 1.2 oz., contains the patented PhytoCellTec. These are the Swiss Green Apple Stem Cells concentrate formula that has been clinically shown to reduce and prevent signs of aging.

DrSkinSpa.com is doctor operated and owned. The company studies and choosesfor sale only the finest products, with clinically proven and natural ingredients. DrSkinSpa.com extends to customers a two-week money-back guarantee for every product sold on their web site. The site also provides customers with a 120% price protection warranty in addition to no cost shipping. Complimentaryaesthetician consultations are also available. DrSkinSpa.com is owned by Crescent Health Center and is based in Anaheim, California.

Read more:
DrSkinSpa.com Announces the Addition of Eminence Bamboo Firming Fluid, 1.2 oz.

Just weeks after invalidating a groundbreaking paper describing a simple technique for generating pluripotent stem cells, professor Kenneth Ka Ho Lee now believes he has identified the correct approach.

Lee, chief of stem cell research at the Chinese University of Hong, spoke to Wired.co.uk in March about his tentative excitement when he read the Nature study in question, published at the start of the year. The proposed Stap cells (stimulus-triggered acquisition of pluripotency) in it were a revelation, because they suggested there was a simple way to generate embryonic-like stem cells that could potentially be used in the treatment of diseases such as Parkinson's. The method involved reprogramming a donor's own adult blood and skin cells (in this case, mice) by exposing them to extreme trauma, such as an acid bath.

Lee could see its potential, but like the rest of the community he had his doubts. While reports circulated that the images published in the Nature study also featured in older papers penned by lead researcher Haruko Obokata of Japan's Riken Centre, Lee set about trying to replicate the experiment himself.

It didn't work.

Since then the Riken Centre has launched an investigation into the legitimacy of the trial, and that investigation today revealed Obokata had indeed falsified information, including results and images of DNA fragments used.

"Actions like this completely destroy data credibility," commented Shunsuke Ishii, head of the investigative committee and a Riken molecular geneticist, at a press conference. "There is no doubt that she was fully aware of this danger. We've therefore concluded this was an act of research misconduct involving fabrication." Obokata has denied the allegations, but Riken says its own research team will be the one to verify the results and carry out the experiment again.

In the interim however, a coauthor on the paper at the centre of the debacle,Charles Vacanti published yet another protocol for the Stap technique, fairly different from the original. Vacanti, of ear-on-a-mouse fame, is a professor at Harvard Medical School and published online what he said was found to be "an effective protocol for generating Stap cells in our lab, regardless of the cell type being studied". It was a combination of the two approaches mentioned in the Naturepaper -- the acid bath, and the trituration process (the application of pressure on the cells using pipettes to induce stress). He describes the latter process as being exerted with force, more so than in the original paper, and over a lengthy period -- twice a day for the first week.

Nature had already rejected Lee's version of experiments for publication last month. Undeterred, he set about applying Vacanti's technique. Liveblogging the experiments on ResearchGate, the open source platform where Lee had published his first set of experiments, the Hong Kong researcher immediately saw the excess stress was leading to rapid cell death among the lung fibroblast cells used.

"The Vacanti protocol put a deal of emphasis on mechanically passing the cells through narrow bore glass pipettes for 30 minutes before acid treatment and then growing the cells on non-adhesive culture plates," Lee told Wired.co.uk. "We conducted these experiments, but it did not induce expression of the pluripotent stem cell markers (Oct4, Sox2 and Nanog)."

Nevertheless, things appeared to turn around. In his preliminary studies Lee has concluded that it could be the extreme stress through trituration, and not the acid bath, that was responsible for creating the Stap cells.

Read the original:
'Fabricated' stem cell paper technique may yet be proven valid

St. Petersburg, FL (PRWEB) April 01, 2014

Sublime Beauty has recently introduced its newest serum which makes a positive impact on aging skin within 30 days.

Cell Renewal | Fibroblast Serum is discounted 35% for 2 days only at the company webstore, SublimeBeautyShop with coupon code CELLRENEW35.

"A key ingredient is Human Fibroblast Conditioned Media, rich in proteins and growth factors, that instruct the skin's fibroblasts to product collagen," says Kathy Heshelow, founder of Sublime Beauty. "The non-embryonic stem cells are powerful indeed - no fillers are used."

The company offers a free brochure about the ingredients on the product page. "We find that our customers want to know about ingredients in the product, what they do and what to expect." says Heshelow. "We offer lots of education on our products."

Sublime Beauty focuses on anti-aging and healthy-skin oriented products, from Skin Brushing and collagen boosters to organic products for the skin. It specializes in serums.

The company offers free standard shipping within the continental U.S and a Sublime Beauty VIP Club. Interested clients can sign up for secret deals and deep discounts as well.

The 35% off sale ends Wednesday at midnight.

Go here to see the original:
The New Scientific Serum That Helps Skin Become Younger and Healthier on Sale at Sublime Beauty Now

Just weeks after invalidating a groundbreaking paper describing a simple technique for generating pluripotent stem cells, professor Kenneth Ka Ho Lee now believes he has identified the correct approach.

Lee, chief of stem cell research at the Chinese University of Hong, spoke to Wired.co.uk in March about his tentative excitement when he read the Nature study in question, published at the start of the year. The proposed Stap cells (stimulus-triggered acquisition of pluripotency) in it were a revelation, because they suggested there was a simple way to generate embryonic-like stem cells that could potentially be used in the treatment of diseases such as Parkinson's. The method involved reprogramming a donor's own adult blood and skin cells (in this case, mice) by exposing them to extreme trauma, such as an acid bath.

Lee could see its potential, but like the rest of the community he had his doubts. While reports circulated that the images published in the Nature study also featured in older papers penned by lead researcher Haruko Obokata of Japan's Riken Centre, Lee set about trying to replicate the experiment himself.

It didn't work.

Since then the Riken Centre has launched an investigation into the legitimacy of the trial, and that investigation today revealed Obokata had indeed falsified information, including results and images of DNA fragments used.

"Actions like this completely destroy data credibility," commented Shunsuke Ishii, head of the investigative committee and a Riken molecular geneticist, at a press conference. "There is no doubt that she was fully aware of this danger. We've therefore concluded this was an act of research misconduct involving fabrication." Obokata has denied the allegations, but Riken says its own research team will be the one to verify the results and carry out the experiment again.

In the interim however, a coauthor on the paper at the centre of the debacle,Charles Vacanti published yet another protocol for the Stap technique. Vacanti, of ear-on-a-mouse fame, is a professor at Harvard Medical School and published online what he said was found to be "an effective protocol for generating Stap cells in our lab, regardless of the cell type being studied". It was a combination of the two approaches mentioned in the Naturepaper -- the acid bath, and the trituration process (the application of pressure on the cells using pipettes to induce stress). He describes the latter process as being exerted with force, more so than in the original paper, and over a lengthy period -- twice a day for the first week.

Nature had already rejected Lee's version of experiments for publication last month. Undeterred, he set about applying Vacanti's technique. Liveblogging the experiments on ResearchGate, the open source platform where Lee had published his first set of experiments, the Hong Kong researcher immediately saw the excess stress was leading to rapid cell death among the lung fibroblast cells used.

"We estimated that there was a 50 percent decrease in cell number," Lee wrote four days ago on the blog. "In the original paper reported in Nature, such decrease in cell count was reported for day two, which is inline with our current experiment. Day three will be critical as this was the time Oct4-GFP expression [an indication that stem cells are generating] was reported for Stap cells. If we find that the cell number decreased even more drastically in our cultures, we will harvest some of the cultures and use them directly for qPCR analysis [quantitative polymerase chain reaction,a screening technique for stem cells]."

Nevertheless, things appeared to turn around. In his preliminary studies Lee has concluded that it could be the extreme stress through trituration, and not the acid bath, that was responsible for creating the Stap cells. "I am shocked and amazed by the qPCR results for the three-day-old control and Stap cultures," he wrote on ResearchGate, alongside a graph of the results. "Totally speechless!"

Link:
'Fabricated' stem cell paper may have just been proven valid

Viruses were traditionally thought to be malicious nanoscopic bearers of death and destruction. But modern science has suggested that while that is sometimes the case, the relationship between viruses and living organisms is a complicated one, as is the question of whether viruses can be truly considered "living" organisms. I. Viruses Can Actually be Useful, Sometimes In case newly discovered mega-viruses -- which rival small bacteria in size, function, and genetic complexity (and are sometimes "infected" by other viruses) -- aren't mind-warping enough, recent evidence suggests that as much of 8 percent of the genetic material found in higher organisms such as humans may be "borrowed" from viral genomes. These pieces of DNA are identifiable, if you know what you're looking for, but long ago lost their ability to depart and jump to new hosts. In that regard, mankind can be viewed as similar in some ways to lichen -- as a collection of multiple fused "organisms" living as one -- as modern man's genetic code consists of virus and traditional eukaryotic genes functioning side by side. The latest wild discovery comes courtesy of Montreal, Quebec, Canada's McGill University.

Professor Bourque states in an interview with National Geographic:

[Acquiring useful genes from viruses] can be faster than just relying on random mutations to get something that might work.

[These genes should be examined] to see if they have also evolved new functional roles, like HERV-H did in stem cells. We suspect that these genes may play important roles in other cell types as well, such as liver, kidney, and brain.

Sources: NATURE STRUCTURAL & MOLECULAR BIOLOGY, National Geographic

Original post:
Primate Stem Cell Creation Appears Driven by Genes From Ancient Virus

These neurons derived from stem cells made from the skin of people with bipolar disorder communicated with one another differently than neurons made from the skin of people without bipolar disorder.(Credit: University of Michigan)

Bipolar disorder is known to run in families, but scientists have yet to pinpoint the genes involved. Now they have a powerful new tool in the hunt: stem cells.

In a first-of-its-kind procedure, researchers from the University of Michigan have created stem cells from the skin of people with bipolar disorder, and then coaxed the cells into neurons. This has allowed scientists, for the first time, to directly measure cellular differences between people with bipolar disorder and people without.

In the future the cells could provide a greater understanding of what causes the disease, and allow for the development of personalized medications specific to each patients cells.

The team from Michigan took skin cell samples from 22 people with bipolar disorder and 10 people without the disorder. Under carefully controlled conditions, they coaxed adult skin cells into an embryonic stem cell-like state. These cells, called induced pluripotent stem cells, then had the potential to transform into any type of cell. With further coaxing, the cells became neurons.

This gives us a model that we can use to examine how cells behave as they develop into neurons. Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium, study co-leader Sue OShea said in a news release.

Researchers published their findings Wednesday in the journalTranslational Psychiatry.

The research team discovered intriguing differences between stem cellsand neuronsfrom bipolar individuals and those from healthy people.

For one thing, bipolar stem cells expressed more genes associated with receiving calcium signals in the brain. Calcium signals play an important role in neuron development and function. Therefore, the new findings support the idea that genetic differences expressed early in life may contribute to the development of bipolar disorder later in life.

Once the stem cells turned into neurons, researchers tested how they reacted to lithium, a typical treatment for the disorder. The tests showed that lithium normalized the behavior of neurons from bipolar patients by altering their calcium signalingfurther confirmation that this cellular pathway should be of key interest in future studies of the disease.

Excerpt from:
Stem Cells Shed Light on Treatments for Bipolar Disorder

Contact Information

Available for logged-in reporters only

Newswise Scientists at University of California, San Diego School of Medicine and Sanford-Burnham Medical Research Institute have shown that by encapsulating immature pancreatic cells derived from human embryonic stem cells (hESC), and implanting them under the skin of diabetic mouse models, sufficient insulin is produced to maintain glucose levels without unwanted potential trade-offs of the technology.

The research, published online in Stem Cell Research, suggests that encapsulated hESC-derived insulin-producing cells may be an effective and safe cell replacement therapy for insulin dependent-diabetes.

Our study critically evaluates some of the potential pitfalls of using stem cells to treat insulin dependent-diabetes, said Pamela Itkin-Ansari, PhD, assistant project scientist in the UC San Diego Department of Pediatrics and adjunct assistant professor in Development, Aging and Regenerative program at Sanford-Burnham.

We have shown that encapsulated hESC-derived insulin-producing cells are able to produce insulin in response to elevated glucose without an increase in the mass or their escape from the capsule, said Itkin-Ansari. These results are important because it means that the encapsulated cells are both fully functional and retrievable.

Previous attempts to replace insulin producing cells, called beta cells, have met with significant challenges. For example, researchers have tried treating diabetics with mature beta cells, but because these cells are fragile and scarce, the method is fraught with problems. Moreover, since the cells come from organ donors, they may be recognized as foreign by the recipients immune system requiring patients to take immunosuppressive drugs to prevent their immune system from attacking the donors cells, ultimately leaving patients vulnerable to infections, tumors and other adverse events.

Encapsulation technology was developed to protect donor cells from exposure to the immune system and has proven extremely successful in preclinical studies.

Itkin-Ansari and her research team previously made an important contribution to the encapsulation approach by showing that pancreatic islet progenitor cells are an optimal cell type for encapsulation. They found that progenitor cells were more robust than mature beta cells to encapsulate, and while encapsulated, they matured into insulin-producing cells that secreted insulin only when needed.

In the study, Itkin-Ansari and her team used bioluminescent imaging to determine if encapsulated cells stay in the capsule after implantation.

Continue reading here:
Stem Cell-Derived Beta Cells Under Skin Replace Insulin

TUESDAY, March 25, 2014 (HealthDay News) -- Brain cells of patients with bipolar disorder act differently than those of people without the mental illness, according to scientists who conducted a stem cell study of the condition.

The investigators said their research might one day lead to a better understanding of bipolar disorder and new treatments for the disease, which causes extreme emotional highs and lows. About 200 million people worldwide have bipolar disorder.

"We're very excited about these findings. But we're only just beginning to understand what we can do with these cells to help answer the many unanswered questions in bipolar disorder's origins and treatment," said study co-leader Dr. Melvin McInnis, a professor of bipolar disorder and depression at the University of Michigan Medical School.

The study authors took skin stem cells from people with and without bipolar disorder and transformed them into neurons similar to brain cells. It's the first time that stem cell lines specific to bipolar disorder have been created, the researchers said.

They discovered distinct differences in how the two sets of neurons behave and communicate with each other. The cells also differed in their response to lithium, the most widely used treatment for bipolar disorder.

The study was published online March 25 in the journal Translational Psychiatry.

"This gives us a model that we can use to examine how cells behave as they develop into neurons," study co-leader Sue O'Shea, a professor in the department of cell and developmental biology and director of the University of Michigan Pluripotent Stem Cell Research Lab, said in a university news release.

"Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium," O'Shea said.

McInnis said it's possible the research could lead to new types of drug trials. If it becomes possible to test new drug candidates in these cells, patients would be spared the current trial-and-error approach that leaves many with uncontrolled symptoms, he said.

More information

Read the original post:
Scientists use stem cells to study bipolar disorder

Researchers have grown embryonic-like stem cells from patients with bipolar disorder and transformed them into brain cells that are already answering questions about the condition.

The cells, which carry the precisely tailored genetic instructions from the patients own cells, behave differently than cells taken from people without the disorder, the researchers report.

Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium," Sue O'Shea, a stem cell specialist at the University of Michigan who led the study, said in a statement.

The work, described in the journal Translational Psychiatry, helps fulfill one of the big promises of stem cells research using a patients own cells to study his or her disease.

Mental illness is especially hard to study. Getting into a living persons brain is almost impossible, and scientists cant deliberately cause it in people in order to study it.

Creating animals such as mice with what looks like human mental illness is imprecise at best.

The University of Michigan team turned instead to what are called induced pluripotent stem cells, or iPS cells. These are ordinary skin cells taken from a patient and tricked into turning back into the state of a just-conceived embryo.

These cells, grown from skin cells taken from people with bipolar disorder, arose from stem cells and were coaxed to become neural progenitor cells -- the kind that can become any sort of nervous system cell. The research showed differences in cell behavior compared with cells grown from people without bipolar disorder.

They are pluripotent, meaning they can become any type of cell there is. In this case, the Michigan team redirected the cells to become neurons the cells that make up much of the brain. "This gives us a model that we can use to examine how cells behave as they develop into neurons, OShea said.

Bipolar disorder, once called manic-depression, is very common, affecting an estimated 3 percent of the population globally. It runs in families, suggesting a strong genetic cause, and is marked by mood swings from depression to feelings of euphoria and creativity thats considered the manic phase.

Follow this link:
Stem Cells Shed Light on Bipolar Disorder

Researchers have grown embryonic-like stem cells from patients with bipolar disorder and transformed them into brain cells that are already answering questions about the condition.

The cells, which carry the precisely tailored genetic instructions from the patients own cells, behave differently than cells taken from people without the disorder, the researchers report.

Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium," Sue O'Shea, a stem cell specialist at the University of Michigan who led the study, said in a statement.

The work, described in the journal Translational Psychiatry, helps fulfill one of the big promises of stem cells research using a patients own cells to study his or her disease.

Mental illness is especially hard to study. Getting into a living persons brain is almost impossible, and scientists cant deliberately cause it in people in order to study it.

Creating animals such as mice with what looks like human mental illness is imprecise at best.

The University of Michigan team turned instead to what are called induced pluripotent stem cells, or iPS cells. These are ordinary skin cells taken from a patient and tricked into turning back into the state of a just-conceived embryo.

These cells, grown from skin cells taken from people with bipolar disorder, arose from stem cells and were coaxed to become neural progenitor cells -- the kind that can become any sort of nervous system cell. The research showed differences in cell behavior compared with cells grown from people without bipolar disorder.

They are pluripotent, meaning they can become any type of cell there is. In this case, the Michigan team redirected the cells to become neurons the cells that make up much of the brain. "This gives us a model that we can use to examine how cells behave as they develop into neurons, OShea said.

Bipolar disorder, once called manic-depression, is very common, affecting an estimated 3 percent of the population globally. It runs in families, suggesting a strong genetic cause, and is marked by mood swings from depression to feelings of euphoria and creativity thats considered the manic phase.

Originally posted here:
Stem Cells Shed Light On Bipolar Disease

Image Caption: These colorful neurons, seen forming connections to one another across synapses, were grown from induced pluripotent stem cells -- ones that were derived from skin cells taken from people with bipolar disorder. New research shows they act, and react to the bipolar drug lithium, differently from neurons derived from people without bipolar disorder. Credit: University of Michigan Pluripotent Stem Cell Research Lab

[ Watch the Video: First Stem Cell Study of Bipolar Disorder Yields Promising Results ]

April Flowers for redOrbit.com Your Universe Online

Bipolar disorder affects 200 million people globally, and yet there are so many questions surrounding the condition. Why are individuals with bipolar disorder prone to manic highs and deep, depressed lows? If there is no single gene to blame, why does bipolar disorder run so strongly in families? And why, with the enormous number of people suffering from bipolar disorder, is it so hard to find new treatments?

A new study from the University of Michigan Medical School, funded by the Heinz C. Prechter Bipolar Research Fund, reveals that the answers might actually be found within our stem cells.

To derive the first-ever stem cell lines specific to bipolar disorder, the research team used skin from individuals who suffer from the condition. They transformed these cells into neurons, similar to those found in the brain, then compared them to cells derived from people without the disorder.

Very specific differences in how these neurons behave and communicate with each other were revealed by the comparison, which also identified striking differences in how the neurons respond to lithium, the most common treatment for bipolar disorder.

This study represents the first time researchers have directly measured differences in brain cell formation and function between individuals with and without bipolar disorder.

The type of stem cells used for this study are called induced pluripotent stem cells (iPSCs). The team coaxed the sample cells to turn into stem cells that held the potential to become any type of cell by exposing the small samples of skin cells to carefully controlled conditions. Further coaxing turned the iPSCs into neurons.

This gives us a model that we can use to examine how cells behave as they develop into neurons. Already, we see that cells from people with bipolar disorder are different in how often they express certain genes, how they differentiate into neurons, how they communicate, and how they respond to lithium, says Sue OShea, Ph.D., an experienced U-M stem cell specialist.

See the original post:
Bipolar Disorder Stem Cell Study Opens Doors To Potential New Treatments

PUBLIC RELEASE DATE:

24-Mar-2014

Contact: Susan Gammon Ph.D. sgammon@sanfordburnham.org 858-795-5012 Sanford-Burnham Medical Research Institute

LA JOLLA, Calif., March 25, 2014 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and UC San Diego School of Medicine scientists have shown that by encapsulating immature pancreatic cells derived from human embryonic stem cells (hESC), and implanting them under the skin in animal models of diabetes, sufficient insulin is produced to maintain glucose levels without unwanted potential trade-offs of the technology. The research suggests that encapsulated hESC-derived insulin-producing cells hold great promise as an effective and safe cell-replacement therapy for insulin-dependent diabetes.

"Our study critically evaluates some of the potential pitfalls of using stem cells to treat insulin-dependent diabetes," said Pamela Itkin-Ansari, Ph.D., adjunct assistant professor in the Development, Aging, and Regenerative Program at Sanford-Burnham, with a joint appointment at UC San Diego.

"We have shown that encapsulated hESC-derived pancreatic cells are able to produce insulin in response to elevated glucose without an increase in the mass or their escape from the capsule. These results are important because it means that the encapsulated cells are both fully functional and retrievable," said Itkin-Ansari.

In the study, published online in Stem Cell Research, Itkin-Ansari and her team used bioluminescent imaging to see if encapsulated cells stay in the capsule after implantation.

Previous attempts to replace insulin-producing cells, called beta cells, have met with significant challenges. For example, researchers have tried treating diabetics with mature beta cells, but because mature cells are fragile and scarce, the method is fraught with problems. Moreover, since the cells come from organ donors, they may be recognized as foreign by the recipient's immune systemrequiring patients to take immunosuppressive drugs to prevent their immune system from attacking the donor's cells, ultimately leaving patients vulnerable to infections, tumors, and other adverse events.

Encapsulation technology was developed to protect donor cells from exposure to the immune systemand has proven extremely successful in preclinical studies.

Itkin-Ansari and her research team previously made an important contribution to the encapsulation approach by showing that pancreatic islet progenitor cells are an optimal cell type for encapsulation. They found that progenitor cells were more robust than mature beta cells to encapsulate, and while encapsulated, they matured into insulin-producing cells, which secreted insulin only when needed.

Originally posted here:
Replacing insulin through stem cell-derived pancreatic cells under the skin

Harvesting samples for producing stem cells can be rather painful. Techniques can involve collecting large amounts of blood, bone marrow or skin scrapes. The reality is intrusive measures such as these can be very off-putting. But what if it was as simple as a finger-prick? Such a DIY approach, which is so easy it can be done at home or in the field without medical staff, has been developed by researchers at Singapore's A*STAR Institute of Molecular and Cell Biology (IMCB).

Unlike previous techniques that require comparatively large cell samples, the ICMB team has managed to successfully reprogram mature human cells into hiPSCs with high efficiency using less than a single drop of blood. Pluripotent stem cells are important in many forms of medical research and treatment as they have the potential to become any other cell type in the body.

"It all began when we wondered if we could reduce the volume of blood used for reprogramming," says Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB. "We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilized less than a drop of finger-pricked blood."

It is hoped that this much less invasive method of sample collection will help attract more donors to increase the samples available to researchers. Blood samples have been found to remain viable for 48 hours after collection and in culture this can be extended to 12 days, opening up remote areas for potential cell harvesting. This could benefit research and treatment with the recruitment of donors with varied ethnicities, genotypes and diseases now possible. It is hoped the technique will also lead to the establishment of large-scale hiPSC banks.

"We were able to differentiate the hiPSCs reprogrammed from Jonathans finger-prick technique, into functional heart cells," says Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper. "This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."

The team has filed a patent for their innovation and their paper has been published online at Stem Cell Translational Medicine.

Source: A*STAR

The rest is here:
Finger-prick technique opens door for DIY stem cell donors

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time -- a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

UC Davis researchers first used human embryonic stem cells obtained from the National Institutes of Health's repository of human stem cells. Embryonic stem cells can become any cell type in the body (i.e., they are pluripotent), and the team successfully coaxed these embryonic stem cells into bladder cells. They then used the same protocol to coax iPS cells made from skin and umbilical cord blood into bladder cells, called urothelium, that line the inside of the bladder. The cells expressed a very unique protein and marker of bladder cells called uroplakin, which makes the bladder impermeable to toxins in the urine.

The UC Davis researchers adjusted the culture system in which the stem cells were developing to encourage the cells to proliferate, differentiate and express the bladder protein without depending upon signals from other human cells, said Kurzrock. In future research, Kurzrock and his colleagues plan to modify the laboratory cultures so that they will not need animal and human products, which will allow use of the cells in patients.

Kurzrock's primary focus as a physician is with children suffering from spina bifida and other pediatric congenital disorders. Currently, when he surgically reconstructs a child's defective bladder, he must use a segment of their own intestine. Because the function of intestine, which absorbs food, is almost the opposite of bladder, bladder reconstruction with intestinal tissue may lead to serious complications, including urinary stone formation, electrolyte abnormalities and cancer. Developing a stem cell alternative not only will be less invasive, but should prove to be more effective, too, he said.

Continue reading here:
Stem cell findings may offer answers for some bladder defects, disease

PUBLIC RELEASE DATE:

21-Mar-2014

Contact: Charles Casey charles.casey@ucdmc.ucdavis.edu 916-734-9048 University of California - Davis Health System

(SACRAMENTO, Calif.) For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patient's defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

"Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders," said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled "Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium."

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patient's own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time a critical element in any tissue engineering application.

"What's exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells," said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. "When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration."

Excerpt from:
Stem cell findings may offer answers for some bladder defects and disease

Home > News > health-news

Washington, March 21 : Researchers have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood.

The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing.

The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.

By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs.

Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors.

Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. Scientists at Institute of Molecular and Cell Biology (IMCB) showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs.

The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency.

The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.

The paper has been published online in the Stem Cell Translational Medicine journal.

See original here:
Now, stem cells created from a drop of blood

Sacramento, CA (PRWEB) March 21, 2014

For the first time, scientists have succeeded in coaxing laboratory cultures of human stem cells to develop into the specialized, unique cells needed to repair a patients defective or diseased bladder.

The breakthrough, developed at the UC Davis Institute for Regenerative Cures and published today in the scientific journal Stem Cells Translational Medicine, is significant because it provides a pathway to regenerate replacement bladder tissue for patients whose bladders are too small or do not function properly, such as children with spina bifida and adults with spinal cord injuries or bladder cancer.

Our goal is to use human stem cells to regenerate tissue in the lab that can be transplanted into patients to augment or replace their malfunctioning bladders, said Eric Kurzrock, professor and chief of the division of pediatric urologic surgery at UC Davis Children's Hospital and lead scientist of the study, which is titled Induction of Human Embryonic and Induced Pluripotent Stem Cells into Urothelium.

To develop the bladder cells, Kurzrock and his UC Davis colleagues investigated two categories of human stem cells. In their key experiments, they used induced pluripotent stem cells (iPS cells), which were derived from lab cultures of human skin cells and umbilical blood cells that had been genetically reprogrammed to convert to an embryonic stem cell-like state.

If additional research demonstrates that grafts of bladder tissue grown from human stem cells will be safe and effective for patient care, Kurzrock said that the source of the grafts would be iPS cells derived from a patients own skin or umbilical cord blood cells. This type of tissue would be optimal, he said, because it lowers the risk of immunological rejection that typifies most transplants.

In their investigation, Kurzrock and his colleagues developed a protocol to prod the pluripotent cells into becoming bladder cells. Their procedure was efficient and, most importantly, the cells proliferated over a long period of time a critical element in any tissue engineering application.

Whats exciting about this discovery is that it also opens up an array of opportunities using pluripotent cells, said Jan Nolta, professor and director of the UC Davis Stem Cell program and a co-author on the new study. When we can reliably direct and differentiate pluripotent stem cells, we have more options to develop new and effective regenerative medicine therapies. The protocols we used to create bladder tissue also provide insight into other types of tissue regeneration.

UC Davis researchers first used human embryonic stem cells obtained from the National Institutes of Healths repository of human stem cells. Embryonic stem cells can become any cell type in the body (i.e., they are pluripotent), and the team successfully coaxed these embryonic stem cells into bladder cells. They then used the same protocol to coax iPS cells made from skin and umbilical cord blood into bladder cells, called urothelium, that line the inside of the bladder. The cells expressed a very unique protein and marker of bladder cells called uroplakin, which makes the bladder impermeable to toxins in the urine.

The UC Davis researchers adjusted the culture system in which the stem cells were developing to encourage the cells to proliferate, differentiate and express the bladder protein without depending upon signals from other human cells, said Kurzrock. In future research, Kurzrock and his colleagues plan to modify the laboratory cultures so that they will not need animal and human products, which will allow use of the cells in patients.

See the article here:
UC Davis Stem-Cell Researchers Findings May Offer Answers for Some Bladder Defects and Disease

Scientists at A*STAR's Institute of Molecular and Cell Biology (IMCB) have developed a method to generate human induced pluripotent stem cells (hiPSCs) from a single drop of finger-pricked blood. The method also enables donors to collect their own blood samples, which they can then send to a laboratory for further processing. The easy access to blood samples using the new technique could potentially boost the recruitment of greater numbers and diversities of donors, and could lead to the establishment of large-scale hiPSC banks.

By genetic reprogramming, matured human cells, usually blood cells, can be transformed into hiPSCs. As hiPSCs exhibit properties remarkably similar to human embryonic stem cells, they are invaluable resources for basic research, drug discovery and cell therapy. In countries like Japan, USA and UK, a number of hiPSC bank initiatives have sprung up to make hiPSCs available for stem cell research and medical studies.

Current sample collection for reprogramming into hiPSCs include invasive measures such as collecting cells from the bone marrow or skin, which may put off many potential donors. Although hiPSCs may also be generated from blood cells, large quantities of blood are usually required. In the paper published online on the Stem Cell Translational Medicine journal, scientists at IMCB showed for the first time that single-drop volumes of blood are sufficient for reprogramming into hiPSCs. The finger-prick technique is the world's first to use only a drop of finger-pricked blood to yield hiPSCs with high efficiency. A patent has been filed for the innovation.

The accessibility of the new technique is further enhanced with a DIY sample collection approach. Donors may collect their own finger-pricked blood, which they can then store and send it to a laboratory for reprogramming. The blood sample remains stable for 48 hours and can be expanded for 12 days in culture, which therefore extends the finger-prick technique to a wide range of geographical regions for recruitment of donors with varied ethnicities, genotypes and diseases.

By integrating it with the hiPSC bank initiatives, the finger-prick technique paves the way for establishing diverse and fully characterised hiPSC banking for stem cell research. The potential access to a wide range of hiPSCs could also replace the use of embryonic stem cells, which are less accessible. It could also facilitate the set-up of a small hiPSC bank in Singapore to study targeted local diseases.

Dr Loh Yuin Han Jonathan, Principal Investigator at IMCB and lead scientist for the finger-prick hiPSC technique, said, "It all began when we wondered if we could reduce the volume of blood used for reprogramming. We then tested if donors could collect their own blood sample in a normal room environment and store it. Our finger-prick technique, in fact, utilised less than a drop of finger-pricked blood. The remaining blood could even be used for DNA sequencing and other blood tests."

Dr Stuart Alexander Cook, Senior Consultant at the National Heart Centre Singapore and co-author of the paper, said "We were able to differentiate the hiPSCs reprogrammed from Jonathan's finger-prick technique, into functional heart cells. This is a well-designed, applicable technique that can unlock unrealized potential of biobanks around the world for hiPSC studies at a scale that was previously not possible."

Prof Hong Wanjin, Executive Director at IMCB, said "Research on hiPSCs is now highly sought-after, given its potential to be used as a model for studying human diseases and for regenerative medicine. Translational research and technology innovations are constantly encouraged at IMCB and this new technique is very timely. We hope to eventually help the scientific community gain greater accessibility to hiPSCs for stem cell research through this innovation."

Story Source:

The above story is based on materials provided by A*STAR. Note: Materials may be edited for content and length.

Go here to read the rest:
Stem cells created from a drop of blood: DIY finger-prick technique opens door for extensive stem cell banking